drugset / Trial / NCT03963973
A 28 Day Parallel Group Study to Assess the Effects of RDN-929
RandomizedParallel-groupQuadruple-blindOther
Summary
Eligibility will be assessed during a screening period of up to 4 weeks. Subjects will take study medication once daily up to and including Day 28. Safety, tolerability and PK will be measured at each visit.
Timeline
- Start
- 2019-05-16
- Primary completion
- 2020-01-22
- Completion
- 2020-01-22
Outcome
Outcome not reported
Stopped: “Participants no longer receiving intervention”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RDN-929 | Unknown | — | Oral |
Indications
No indication recorded.